Sigyn Therapeutics (SIGY) Research & Development (2020 - 2025)
Sigyn Therapeutics (SIGY) posted Research & Development of $29681.0 for Q3 2025, up 296.7% sequentially from $7482.0 in Q2 2025, and down 85.6% YoY from $206161.0 in Q3 2024.
Sigyn Therapeutics (SIGY) Research & Development (2020 - 2025) Analysis & Trends
Sigyn Therapeutics has reported Research & Development for 6 years, with the latest figure at $29681.0 in Q3 2025.
- Quarterly Research & Development fell 85.6% year-over-year to $29681.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $140101.0 (down 84.35% YoY) and the FY2024 annual result came in at $773279.0, down 3.12% from the prior year.
- Research & Development advanced to $29681.0 in Q3 2025 per SIGY's latest filing, from $7482.0 in the prior quarter.
- Over five years, Research & Development peaked at $250259.0 in Q4 2021 and troughed at $7482.0 in Q2 2025.
- A 5-year average of $157151.0 and a median of $154683.0 in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2021 and 2025: Research & Development jumped 4615.17% in 2021, then tumbled 96.89% in 2025.
- Over 5 years, Research & Development stood at $250259.0 in 2021, then plunged by 43.71% to $140861.0 in 2022, then jumped by 53.3% to $215933.0 in 2023, then tumbled by 56.42% to $94096.0 in 2024, then sank by 68.46% to $29681.0 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $29681.0, $7482.0, and $8842.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Sigyn Therapeutics | 48,161.31 | -37,409.69 | - | 29,681.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 29,681.00 |
| Jun 30, 2025 | 7,482.00 |
| Mar 31, 2025 | 8,842.00 |
| Dec 31, 2024 | 94,096.00 |
| Sep 30, 2024 | 206,161.00 |
| Jun 30, 2024 | 240,429.00 |
| Mar 31, 2024 | 232,593.00 |
| Dec 31, 2023 | 215,933.00 |
| Sep 30, 2023 | 215,230.00 |
| Jun 30, 2023 | 219,159.00 |
| Mar 31, 2023 | 147,843.00 |
| Dec 31, 2022 | 140,861.00 |
| Sep 30, 2022 | 133,770.00 |
| Jun 30, 2022 | 154,683.00 |
| Mar 31, 2022 | 228,342.00 |
| Dec 31, 2021 | 250,259.00 |
| Sep 30, 2021 | 227,503.00 |
| Jun 30, 2021 | 139,736.00 |
| Mar 31, 2021 | 93,266.00 |
| Dec 31, 2020 | 417,384.00 |